RU58841 Quick Details:
RU-58841 RU58841 Quack Detail
Application Specific androgen receptor antagonist
Molar Mass 369.34 g/mol
Chemical Formula C17H18F3N3O3
Synonyms PSK-3841, HMR-3841
Storage Minimize open air exposure, store in a cool dry place
|Synonyms:||4-(4,4-Dimethyl-2,5-dioxo-3-(4-hydroxybutyl)1-imidazolidinyl)-2-(trifluoromethyl)benzonitrile; RU58841; 4-[3-(4-Hydroxybutyl)-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl]-2-(trifluoromethyl)benzonitrile|
|Boiling Point(C):||493.6C at 760 mmHg|
RU 58841 is a specific androgen receptor antagonist or anti-androgen used as a topical treatment for acne, androgenetic alopecia and hirsutism. RU 58841 displays high affinity for the hamster prostate and flank organ (F.O.) androgen receptors. In vivo, when topically applied, it exerts a potent dose-dependent regression of F.O. area at a dose as low as 1 microgram/animal while being devoid of antiandrogenic activity on deep accessory sex organs and of any effect on test level up to 100 micrograms/animal. RU 58841 has a dramatic effect on hair regrowth
RU-58841 is a new non-steroidal specific topical antiandrogen: a candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism. The potent localized inhibition of sebaceous glands by RU 58841 demonstrates the excellent potential of this compound as a topical drug for the treatment of acne and other androgen-mediated disorders. Synonym: RU-58841; RU58841; RU 58841.
RU58841 is the drug for the treatment of hair loss dwindled, perhaps due more to commercial potential and chemical stability reasons than efficacy as the later studies of RU58841 have focused on different chemical forms of the drug and combining it with various nanoparticles to enhance delivery.
the drug for the treatment of hair loss dwindled, perhaps due more to commercial potential and chemical stability reasons than efficacy as the later studies of RU58841 have focused on different chemical forms of the drug and combining it with various nanoparticles to enhance delivery. Recent years have seen the odd study pop up in relation to RU58841 and the treatment of acne and prostate cancer, which are conditions also driven however, the most recent study published in relation to RU58841 was back in 2008.